Overview

Zymeworks has an extensive and diverse portfolio of therapeutic candidates in its pipeline targeted for a number of potential indications. The candidates include bi-specific antibodies and bi-specific ADCs that confers therapeutic efficacy by a number of different mechanisms of action including signal blockade, recruitment of effector cells, and toxin-mediated cytotoxicity.